Natural Exposure to Cutaneous Anthrax Gives Long-Lasting T Cell Immunity Encompassing Infection-Specific Epitopes


Ingram R. J. , Metan G. , Maillere B., DOĞANAY M., ÖZKUL Y., Kim L. U. , ...Daha Fazla

JOURNAL OF IMMUNOLOGY, cilt.184, ss.3814-3821, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 184 Konu: 7
  • Basım Tarihi: 2010
  • Doi Numarası: 10.4049/jimmunol.0901581
  • Dergi Adı: JOURNAL OF IMMUNOLOGY
  • Sayfa Sayıları: ss.3814-3821

Özet

There has been a long history of defining T cell epitopes to track viral immunity and to design rational vaccines, yet few data of this type exist for bacterial infections. Bacillus anthracis, the causative agent of anthrax, is both an endemic pathogen in many regions and a potential biological warfare threat. T cell immunity in naturally infected anthrax patients has not previously been characterized, which is surprising given concern about the ability of anthrax toxins to subvert or ablate adaptive immunity. We investigated CD4 T cell responses in patients from the Kayseri region of Turkey who were previously infected with cutaneous anthrax. Responses to B. anthracis protective Ag and lethal factor (LF) were investigated at the protein, domain, and epitope level. Several years after anti biotic-treated anthrax infection, strong T cell memory was detectable, with no evidence of the expected impairment in specific immunity. Although serological responses to existing anthrax vaccines focus primarily on protective Ag, the major target of T cell immunity in infected individuals and anthrax-vaccinated donors was LF, notably domain IV. Some of these anthrax epitopes showed broad binding to several HLA class alleles, but others were more constrained in their HLA binding patterns. Of specific CD4 T cell epitopes targeted within LF domain IV, one is preferentially seen in the context of bacterial infection, as opposed to vaccination, suggesting that studies of this type will be important in understanding how the human immune system confronts serious bacterial infection. The Journal of Immunology, 2010,184: 3814-3821.